

Company name	EU / non-EU	Technology	Tentative timelines
Aegis	Non-EU, planning to add EU capacity	DNA	phase III to begin before end 2020; interim data to EMA in March 2021
Arcturus	Non-EU; planning to add EU capacity	mRNA	Phase 1 to start Q3 2020
Bavarian Nordic	EU	capsid viral like particle	Phase III around April 2021; aiming for authorisation Q3 2021
Panacea Refana	Non-EU; not planning to add EU capacity	inactivated viral vector	Phase III Jan - June 2021
PepTC	EU	Poly-peptide vaccine non-replicating viral vector	April 2021 phase II (depending on funding)
Reithera	EU		phase II / III to start Q4 2020
Valneva	EU	inactivated viral vector	phase I to start end 2020
Vaxine	Non-EU; planning to add EU capacity	recombinant spike protein	phase I started July 2020
Ziphys	EU	mRNA	phase I to start end 2020
Takis / Rottapharm	EU	DNA	phase I-II by Nov 2020; phase III June 2021 - end 2021
Ciloa	EU	Ciloa	phase I end of year

Plans and proposal for arrangement with EU

180mn euros to fund capacity for 300mn doses (1 dose for immunity). Alternatives: 90mn for 90mn; 30mn for 45mn. Price of vaccine around 6 euros per dose.

Can produce 1bn doses / annum of drug substance from April 2021. Asking for help with fill/finish: internal investments for capacity of 150m / annum; contract with CMO for 150m annum.

Company with manufacturing in India; have expressed interest in supplying EU market

Have asked for 55m pounds to carry out phase II and III clinical trials from April 2021 onwards (with idea of applying for CMA in November 2021)

Request for 100mn euros of funding in return for 100mn doses; reserving capacity of 400mn doses.

current capacity: 110mn doses in 2021; 210mn doses in 2022. Just concluded deal with UK - impact of this on offer / request not yet clear

looking to use a franchise model for manufacturing in different regions, possible scale / needs not yet clear

Looking for 30mn to fund phase I and II. Plans to start production Q2 2021; manufacturing preparation Q2-Q4 2021

looking for c75m in funding for development and manufacturing; not yet clear what offer in return is looking for support for CTs and development

Other points of interest

Funds treated as down-payment. If unsuccessful, to be repaid via number of suggested means (e.g. other products; offering delivery technology to other candidates)

Final product will be lyophilised mRNA

Open to use their capacity for other candidates in case of non-success; proposed pricing principles not yet known

Flexible in use of capacity if their candidate unsuccessful

State of play

Slide deck circulated to Board, exploratory discussion on terms held

Met Com team on 1 July; follow-up call on 8 July.

Slide deck circulated to Board; exploratory discussion on terms held

Meeting with COM team on 6 July; slide deck and draft terms sheet requested

Meeting with representatives on 30 June to explain EU scheme

Proposal received from PepTC on 2 July. As framed, it reads more like a request for a grant than something suitable for an APA. We have suggested to them they should contact the EIB / DG RTD to discuss grant possibilities in parallel.

Slide deck circulated to Board, exploratory discussions on terms held.

Draft terms sheet received but doesn't take account of Valneva supply agreement with UK; will ask for updated version

Initial meeting 8 July, animal data received

Intro meeting on 1 July, awaiting draft written materials

Meeting on 22 July, draft terms sheet requested

Call on 15 July, directed to EIB to discuss support